Clinical trials
Sexually Transmitted Infections (Not HIV or Hepatitis) clinical trials
Below are recruiting sexually transmitted infections (not hiv or hepatitis) clinical trials, each written for real people, not researchers. We’re tracking 794 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06919614RecruitingPhase 3
Testing STIs to Improve PrEP Use in Pregnancy
This trial tests whether STI testing during pregnancy helps more women start and stay on PrEP (a daily pill that prevents HIV). If you join, you'll help find better ways to protect both mother and baby from HIV.
GaboroneAges Any age - NCT06996938Recruiting
Sexual health screening for women in vulnerable situations
This study offers sexual health checkups and prevention services to women who are in difficult social or financial situations, including those without stable housing or who have sold sex for money. The goal is to see if these services are helpful and acceptable.
ParisAges 18 years+ - NCT07215325RecruitingPhase 4
Can doxycycline prevent STIs in men?
This trial tests if taking doxycycline after sex can lower the risk of getting sexually transmitted infections (STIs) in men who have sex with men and are at higher risk.
Atlanta, GeorgiaAges 18 years+ - NCT00404989Recruiting
Pregnancy drug safety registry for people with HIV treatment
This trial is a pregnancy registry that collects information about birth outcomes when certain HIV medicines are taken during pregnancy. It helps detect any major birth defects so future pregnancies can be safer.
Wilmington, North CarolinaAges 12–60 - NCT07429864Recruiting
Bulevirtide for hepatitis D: bile acids and gut bacteria
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
RomaAges 18 years+ - NCT04984772Enrolling by invitation
HIV and hepatitis B coinfection follow-up study in Europe
This study follows people who have both HIV and hepatitis B over time to better understand how the infection responds after starting treatment. Your information (and sometimes stored blood samples) helps researchers track changes from the start of therapy to about 2 years later.
Ages 16 years+ - NCT07358910Recruiting
Tracking infectious diseases in communities
This study looks at how infections spread in villages in Cambodia. If you live in a participating village, you might help us understand and prevent disease outbreaks.
Phnom Penh, Phnom PenhAges 2–75 - NCT06638320Recruiting
Hepatitis Delta Risk Study in Hepatitis B Patients
This study looks for hepatitis delta virus (a virus that only affects people with hepatitis B) in patients who have chronic hepatitis B. Researchers want to understand how common this co-infection is and which patients are at highest risk.
Hà Nội, Northern VietnamAges 16 years+ - NCT05668026RecruitingPhase 1/Phase 2
Venetoclax to shrink HIV reservoir in people on stable ART
This Phase 1/2 study tests whether venetoclax can help reduce the “HIV reservoir,” which is a hidden group of HIV-infected cells, while you stay on your usual HIV treatment. It also looks at whether the drug helps these infected cells die off in a controlled, safe way.
AarhusAges 18–65 - NCT05719441RecruitingPhase 2
Antibodies plus early HIV treatment to try for HIV remission
This study tests whether giving special HIV-fighting antibodies along with starting standard HIV medicine soon after infection can help you reach “HIV remission.” It may reduce or delay the return of detectable virus, but you must be willing to follow close monitoring and specific study steps.
Birmingham, AlabamaAges 18–70 - NCT07476339RecruitingPhase 4
Returning to HIV Care with Biktarvy
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
Clearwater, FloridaAges 18 years+ - NCT07610772RecruitingPhase 1
Safety study of a new hepatitis B antibody for hepatitis D
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
AarhusAges 18–70 - NCT05147519Recruiting
Observes HIV and other infections to learn who gets them
This is an observational study that follows people to better understand how HIV and other infections (like sexually transmitted infections) happen and change over time. It may help researchers improve prevention and care, but it is mainly for monitoring rather than testing a new treatment.
Kericho, Kericho CountyAges 14–55 - NCT06484335RecruitingPhase 1
Testing an HIV vaccine and antibody combo for treatment-free control
This study tests a combination of an HIV vaccine and an antibody infusion to see if your immune system can control HIV without daily pills. You would temporarily stop your HIV medication under close monitoring and restart if needed.
Pathum Wan, BangkokAges 18–60 - NCT07317687Recruiting
Rapid HIV, Hep C, and Syphilis Testing in Street Medicine
This trial offers free rapid testing for HIV, hepatitis C, and syphilis during street medicine visits. It helps find infections early so you can get connected to care.
Harpers Ferry, West VirginiaAges 18 years+ - NCT04553081RecruitingPhase 4
Switching HIV treatment: 2-drug versus 3-drug plan
This trial compares two different HIV treatment plans: keeping you on a 2-drug regimen versus switching to a 3-drug regimen. It’s designed for people whose HIV is well controlled and looks at whether the switch is safe and effective.
GhentAges 18 years+ - NCT07024641RecruitingPhase 1
Safety study of GIGA-2339 for chronic Hepatitis B
This study tests an experimental antibody (GIGA-2339) given as an infusion to people with chronic Hepatitis B. It aims to see if the drug is safe and how the body processes it, possibly helping to control the virus.
Chandler, ArizonaAges 18 years+ - NCT04375800RecruitingPhase 2
Doravirine for children with HIV infection and stable treatment
This Phase 2 study tests doravirine (a type of HIV medicine) in children with HIV who are about 4 weeks to under 12 years old and weigh under 45 kg. It aims to see whether this regimen can control the virus safely, and some children may continue into an extension if they benefit.
Aurora, ColoradoAges 4 weeks–11 years - NCT04648046RecruitingPhase 1/Phase 2
CAR-T cell treatment for HIV infection
This early-phase study tests whether CAR-T cells (immune cells modified to recognize HIV) can help control HIV. You may be asked to briefly pause HIV medicines to see how well the treatment controls the virus.
Sacramento, CaliforniaAges 18–65 - NCT05051098Recruiting
Registry for people with hepatitis B infection
This study is a registry, meaning it collects health information from people living with hepatitis B rather than giving a new treatment. It may help researchers better understand different hepatitis B groups and outcomes over time.
HanoverAges 18 years+ - NCT05590455RecruitingPhase 2
Testing a TNF-blocking drug to reduce death in HIV and TB meningitis
This Phase 2 trial studies whether a TNF-blocking medicine can lower the risk of death in people with HIV who also have TB meningitis. You would receive standard TB meningitis treatment plus the study drug, if you meet the criteria.
Rio de JaneiroAges 18 years+ - NCT05652088Recruiting
Study gut immune tissue in HIV cure efforts
This study looks at how immune tissue in the gut may be involved in curing HIV. You may be asked to have two colonoscopies while on an HIV “cure-related” treatment, so researchers can collect tissue samples to understand what’s happening in your body.
New York, New YorkAges 18–75 - NCT06082336Recruiting
A new rapid blood test for HIV, Hepatitis B, and Hepatitis C
This trial tests a new rapid blood test (called MaGIA IBC) that checks for HIV, Hepatitis B, and Hepatitis C all at once. It's for people who already know or might have one of these infections. Participating helps see if this test works well in real-world settings.
Marseille, FranceAges 18 years+ - NCT06395129Recruiting
Better syringes for people who inject drugs
This study provides safer, low-dead-space syringes to people who inject drugs to help reduce the spread of infections like HIV and hepatitis C. It is designed for people in low- and middle-income countries who use needle exchange programs.
YerevanAges 18 years+
Hear when a new Sexually Transmitted Infections (Not HIV or Hepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sexually transmitted infections (not hiv or hepatitis)?
- Yes. Clin2 currently lists 794 recruiting sexually transmitted infections (not hiv or hepatitis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sexually transmitted infections (not hiv or hepatitis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sexually transmitted infections (not hiv or hepatitis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.